DROSHA rs10719 T>C遗传变异与胃癌临床病理特征及预后的相关性分析  

Correlation of DROSHA rs10719 T>C and Clinicopathologic Features and Prognosis of Gastric Cancer

作　　者：李俊[1] 钟军[1] 李国庆[1] 吴新生[1] 彭丽香[1] 

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2016年第12期1929-1932,共4页The Practical Journal of Cancer

摘　　要：目的 研究DROSHA rs10719 T〉C与胃癌临床病理特征及预后的关系。方法 97例接受奥沙利铂联合氟尿嘧啶类药物术后辅助化疗的Ⅰ~Ⅲ期胃癌患者,分析rs10719遗传变异与胃癌临床病理特征及预后的相关性。结果全组患者2年DFS为60.8%,3年OS为73.8%。显性模型与淋巴结转移相关,TC＋CC基因型患者淋巴结转移发生率低于TT基因型（P=0.031）。显性模型与临床分期显著相关,TT基因型中Ⅲ期患者明显多于TC＋CC基因型（P=0.021）。有、无淋巴结转移患者3年OS分别为89.3%和63.3%（P=0.013）,Ⅰ、Ⅱ、Ⅲ期患者3年OS分别为100.0%、88.6%和55.8%（P=0.015）,具有显著统计学差异。rs10719遗传变异与患者生存无明显相关性。多因素预后分析显示,淋巴结状态（P=0.014,RR：9.556,95%CI：1.586~57.590）为独立预后因素。结论 DROSHA rs10719 T〉C遗传变异可能与胃癌患者淋巴结转移状态及临床分期相关。Objective To investigate the association between DROSHA rs10719 T 〉 C and clinicopathologic characteris- tics and prognosis of gastric cancer patients. Methods 97 patients with stage Ⅰ-Ⅲ gastric cancer treated with radical gastrecto- my and adjuvant chemotherapy of oxaliplatin and fluorouracils were analyzed. Correlation between DROSHA rs10719 T 〉 C and clinicopathologic characteristics and prognosis of gastric cancer patients were analyzed. Results 2-year DFS rate was 60.8% and 3-year OS rate was 73.8%. In dominant model, we found that rs10719 TC ＋ CC genotype carriers were less likely to develop lymph node metastasis （P=0.031 ）. Compared with TC ＋ CC genotype carriers,more patients with Tr genotype were in stage 11I （P = 0. 021 ）. 3-year OS was significantly different between patients with or without lymph node metastasis （89.3% vs 63.3%, P =0.013） and among patients with stage Ⅰ-Ⅲ disease （ 100.0% ,88.6% and 55.8% ,P =0.015）. rs10719 was not related with survival. Multi-variants＇ cox regression analysis showed that lymph node status （ P = 0. 014, RR： 9. 556,95% CI ： 1. 586 - 57. 590） was independent prognostic factor. Conclusion DROSHA rs10719 T 〉 C could be associated with lymph node metasta- sis and clinical stage of gastric cancer patients.

关 键 词：DROSHA 遗传变异 临床病理特征 预后 

分 类 号：R73-36[医药卫生—肿瘤]